Index,index,P,I,C,O,S,matches_criteria,reasoning
0,0,patients with unresectable or metastatic hepatocellular carcinoma,camrelizumab plus rivoceranib,sorafenib,progression-free survival and overall survival,"randomized, open-label, international phase 3 trial",True,matches all PICOS criteria
1,1,patients with advanced hepatocellular carcinoma,LEN combined with transarterial chemoembolization,LEN monotherapy,overall survival,"multicenter, randomized, open-label, parallel group, phase III trial",False,intervention does not match ICIs
2,2,patients with advanced hepatocellular carcinoma,nivolumab monotherapy,sorafenib monotherapy,overall survival,"randomised, open-label, phase 3 trial",True,matches all PICOS criteria
3,3,patients with advanced HCC/PC/OC,anti-GPC3-7×19 CAR-T treatment,not specified,tumor suppression ability,phase 1 clinical trial,False,intervention and comparison do not match ICIs
4,4,patients with unresectable hepatocellular carcinoma,FOLFOX-HAIC,TACE,overall survival,"randomized, multicenter, open-label trial",False,intervention does not match ICIs
5,5,patients with advanced HCC previously treated with sorafenib,nivolumab plus ipilimumab,not specified,objective response rate,"multicenter, open-label, multicohort, phase 1/2 study",False,comparison not specified and study design not RCT
6,6,patients with advanced HCC previously treated with a multityrosine kinase inhibitor,DNA plasmid PTCV plus pembrolizumab,not specified,objective response rate,"single-arm, open-label, phase 1/2 study",False,comparison not specified and study design not RCT
7,7,"patients with locally advanced, unresectable hepatocellular carcinoma",TACE and stereotactic body radiotherapy followed by avelumab,not specified,proportion of patients amenable to curative treatment,"single-arm, phase 2 trial",False,comparison not specified and study design not RCT
8,8,patients with recurrent/residual HCC,proton beam radiotherapy,radiofrequency ablation,2-year local progression-free survival,phase III non-inferiority trial,False,intervention does not match ICIs
9,9,patients with unresectable hepatocellular carcinoma,TACE plus sorafenib,TACE alone,progression-free survival,randomised trial,False,intervention does not match ICIs
10,10,patients with intermediate-stage hepatocellular carcinoma,lenvatinib plus pembrolizumab plus TACE,placebos plus TACE,overall survival and progression-free survival,"prospective, double-blind randomized phase 3 study",True,"Matches PICOS criteria with specified population, intervention, comparison, outcomes, and study design."
11,11,patients with intermediate-stage HCC,yttrium 90 transarterial radioembolization,doxorubicin drug-eluting bead TACE,time to overall tumor progression and overall survival,single-center prospective randomized controlled trial,False,Does not match PICOS criteria as the intervention is not an immune checkpoint inhibitor.
12,12,patients with advanced HCC,anti-PD-1 immunotherapy,not specified,early detection and assessment of immunotherapy efficacy,not specified,False,Does not match PICOS criteria due to lack of comparison and study design details.
13,13,patients with HCC,anti-PD-1 therapy,not specified,response and immune-related adverse events,not specified,False,Does not match PICOS criteria due to lack of comparison and study design details.
14,14,cancer patients with neurologic immune-related adverse events,anti-PD-1 or anti-PD-L1 monotherapy or combination therapy,cancer control patients without irAE-n,immune cell dysregulation and diagnostic markers,observational cohort study,False,Does not match PICOS criteria as the population and outcomes do not align with the target criteria.
15,15,patients with resectable HCC,camrelizumab plus apatinib,not specified,"major pathological reactions, objective response rate, relapse-free survival","open-label, single-arm, phase II clinical trial",False,Does not match PICOS criteria due to lack of comparison and the study design is not a randomized controlled trial.
16,16,patients with resectable HCC,neoadjuvant cemiplimab,not specified,"significant tumour necrosis, overall response, adverse events","single-arm, open-label, phase 2 trial",False,Does not match PICOS criteria due to lack of comparison and the study design is not a randomized controlled trial.
17,17,patients with unresectable intermediate-advanced HCC,lenvatinib plus anti-PD-1 antibodies,not specified,"conversion success rate, objective response rate, progression-free survival","single-arm, phase II study",False,Does not match PICOS criteria due to lack of comparison and the study design is not a randomized controlled trial.
18,18,patients with sorafenib-failed HCC,pembrolizumab,not specified,objective response rate,single-arm prospective phase II trial,False,Does not match PICOS criteria due to lack of comparison and the study design is not a randomized controlled trial.
19,19,patients with unresectable HCC,regorafenib-nivolumab,not specified,"objective response rate, progression-free survival, overall survival","multicenter, single-arm, phase 2 trial",False,Does not match PICOS criteria due to lack of comparison and the study design is not a randomized controlled trial.
20,20,patients with pretreated advanced hepatocellular carcinoma,apatinib,placebo,overall survival,"randomised, double-blind, placebo-controlled, phase 3 trial",False,Intervention is not an immune checkpoint inhibitor.
21,21,patients with advanced hepatocellular carcinoma,nivolumab monotherapy,not specified,"objective response rate, overall survival",not specified,False,Comparison and study design not specified.
22,22,HCC patients receiving TACE therapy,FZJDXJ combined with standard treatment,standard treatment alone,"overall survival, progression-free survival",randomized controlled clinical trial,False,Intervention is not an immune checkpoint inhibitor.
23,23,patients with resectable hepatocellular carcinoma,nivolumab with or without ipilimumab,not specified,"safety and tolerability, overall response, progression-free survival","single-centre, randomised, open-label, phase 2 trial",False,Comparison not specified.
24,24,patients with early-stage recurrent hepatocellular carcinoma,repeat hepatectomy,percutaneous radiofrequency ablation,"overall survival, repeat recurrence-free survival",open-label randomized clinical trial,False,Intervention is not an immune checkpoint inhibitor.
25,25,patients with unresectable hepatocellular carcinoma,tremelimumab in combination with durvalumab,not specified,"overall survival, progression-free survival",not specified,False,Comparison and study design not specified.
26,26,patients with early-stage resectable hepatocellular carcinoma,neoadjuvant PD-1 blockade plus stereotactic body radiotherapy,not specified,"surgery delay, radiographic and pathological tumor response",phase 1b trial,False,Comparison not specified.
27,27,patients with advanced hepatocellular carcinoma,MTL-CEBPA,not specified,radiologic regression of tumors,phase I trial,False,Intervention is not an immune checkpoint inhibitor.
28,28,patients with HCC with microvascular invasion,adjuvant sintilimab,active surveillance,"recurrence-free survival, overall survival","multicenter, open-label, randomized, controlled, phase 2 trial",True,Matches all PICOS criteria.
29,29,patients with locally advanced HCC,locoregional high-dose autologous NK cell therapy,not specified,"objective response rate, progression-free survival, overall survival","prospective, open-label, phase I trial",False,Intervention is not an immune checkpoint inhibitor.
30,30,patients with unresectable hepatocellular carcinoma,atezolizumab plus bevacizumab,not specified,overall survival and progression-free survival,observational study,False,No comparison group specified and not a randomized controlled trial.
31,31,patients with locally advanced unresectable HCC,Y90-radioembolization plus durvalumab,not specified,"time to progression, overall survival, progression-free survival, objective response rate",phase I/IIa pilot trial,False,No comparison group specified and not a randomized controlled trial.
32,32,patients with recurrent intermediate-stage HCC and positive MVI,SOR-TACE,TACE alone,"overall survival, progression-free survival, objective response rate","phase 3, open-label, multicenter randomized clinical trial",True,Matches all PICOS criteria.
33,33,patients with hepatocellular carcinoma,radiation therapy,not specified,"local control, progression-free survival",not specified,False,No comparison group specified and study design not specified.
34,34,patients with advanced hepatocellular carcinoma,camrelizumab plus apatinib,not specified,"objective response rate, progression-free survival, 12-month survival rate","nonrandomized, open-label, multicenter, phase II study",False,No comparison group specified and not a randomized controlled trial.
35,35,patients with metastatic solid tumors including HCC,CD8 PET imaging with (89)Zr-Df-IAB22M2C,not specified,"biodistribution, radiation dosimetry, semiquantitative evaluation of uptake",phase 1 first-in-humans PET imaging study,False,No comparison group specified and not a randomized controlled trial.
36,36,patients with small hepatocellular carcinoma,laparoscopic liver resection,radiofrequency ablation,"overall survival, recurrence-free survival",single-centre RCT,True,Matches all PICOS criteria.
37,37,sorafenib-treated patients with advanced hepatocellular carcinoma,nivolumab plus ipilimumab,not specified,"objective response rate, duration of response, overall survival",randomized clinical trial,False,No comparison group specified.
38,38,patients with unresectable HCC awaiting DDLT,SBRT,not specified,"progression-free survival, objective response rates, overall survival",phase 2 nonrandomized controlled trial,False,No comparison group specified and not a randomized controlled trial.
39,39,patients with intrahepatic cholangiocarcinoma,immune checkpoint blockades,not specified,"tumor ecosystem analysis, prognostic significance of SPP1(+) TAMs",single-cell RNA sequencing analysis,False,No comparison group specified and not a randomized controlled trial.
40,40,patients with advanced stage HCC,"lenvatinib, sintilimab plus TACE",not specified,"progression-free survival, objective response rate",single-arm phase II trial,False,"No comparison group specified, not a randomized controlled trial"
41,41,patients with unresectable hepatocellular carcinoma,"STRIDE regimen, durvalumab",sorafenib,"overall survival, patient-reported outcomes",phase III randomized controlled trial,True,Matches all PICOS criteria
42,42,patients with HCC scheduled for TACE,2D and 3D CE US,CE MRI or CT,sensitivity and specificity in detecting residual HCC,prospective multicenter trial,False,Intervention and outcome do not match PICOS criteria
43,43,patients with hepatocellular carcinoma with portal vein tumor thrombus,sorafenib plus transarterial chemoembolization,sorafenib alone,"recurrence-free survival, overall survival","phase 3, multicenter, randomized clinical trial",True,Matches all PICOS criteria
44,44,patients with HCC meeting transplant criteria,proton beam radiotherapy,transarterial chemoembolization,"overall survival, progression-free survival",randomized trial,True,Matches all PICOS criteria
45,45,patients diagnosed with HCC,DEB-TACE using small-size microspheres,not specified,"objective response rate, progression-free survival","prospective, single-arm, multicenter study",False,"No comparison group specified, not a randomized controlled trial"
46,46,patients with liver-confined HCC,TACE plus pembrolizumab,not specified,"progression-free survival, overall survival",not specified,False,No comparison group or study design specified
47,47,patients with very early- to intermediate-stage HCCs,HepaVac-101 vaccine,not specified,"safety, tolerability, antigen-specific T-cell responses","single-arm, first-in-human phase I/II multicenter trial",False,"No comparison group specified, not a randomized controlled trial"
48,48,patients with HCC,not specified,not specified,prognostic and treatment strategies based on tumor evolution,prospective cohort study,False,"Intervention and comparison not specified, not a randomized controlled trial"
49,49,patients with small- and medium-sized HCC,microwave ablation,radiofrequency ablation,"local tumor progression, disease-free survival, overall survival",prospective trial,True,Matches all PICOS criteria
50,50,patients with unresectable hepatocellular carcinoma,bavituximab plus pembrolizumab,not specified,"objective response rate, progression-free survival, overall survival",single-arm phase 2 trial,False,No comparison group specified and not a randomized controlled trial.
51,51,patients with unresectable HCC,selective internal radiation therapy (SIRT),not specified,"downstaging achievement, overall survival","retrospective, observational study",False,No comparison group specified and not a randomized controlled trial.
52,52,patients with hepatocellular carcinoma,TACE-DEB,SBRT,"time to progression, local control, overall survival",multicenter randomized trial,True,Matches all PICOS criteria.
53,53,patients with unresectable hepatocellular carcinoma,TACE combined with envafolimab and lenvatinib,not specified,"objective response rate, disease control rate, progression-free survival",not specified,False,No comparison group specified and study design not specified.
54,54,patients with intermediate/advanced HCC,adjuvant immune checkpoint inhibitors,treatment without adjuvant ICIs,"recurrence-free survival, overall survival",prospectively-collected multicenter database,False,Not a randomized controlled trial.
55,55,patients with unresectable hepatocellular carcinoma and liver-only disease,SIRT followed by nivolumab,not specified,"objective response rate, time to progression, overall survival","single-arm, multicenter, open-label, phase 2 trial",False,No comparison group specified and not a randomized controlled trial.
56,56,patients with a solitary HCC ≤8 cm,SABR,thermal ablation or best other standard of care therapy,"freedom from local progression, progression free survival, overall survival","phase II, prospective, randomised trial",True,Matches all PICOS criteria.
57,57,patients with chronic hepatitis B and biopsy-proven histological significant fibrosis,entecavir-based therapy,not specified,"incidence of HCC, liver-related events",randomized controlled trial,False,Population does not match the target criteria.
58,58,patients with HCC and Vp4 PVTT,irradiation stent placement with 125 I plus TACE,sorafenib plus TACE,"overall survival, hepatic function, time to symptomatic progression",multicenter randomized controlled trial,True,Matches all PICOS criteria.
59,59,patients with recurrent or oligometastatic HCC,SBRT plus sintilimab,not specified,"progression-free survival, overall survival, local control rate",not specified,False,No comparison group specified and study design not specified.
60,60,patients with hepatocellular carcinoma,acyclic retinoid (ACR),not specified,HCC recurrence and long-term prognosis,phase 3 clinical trial,False,Intervention is not immune checkpoint inhibitors and comparison is not specified.
61,61,patients with advanced hepatocellular carcinoma,sitravatinib with/without tislelizumab,not specified,objective response rate,phase Ib/II study,False,Intervention includes but is not limited to immune checkpoint inhibitors and comparison is not specified.
62,62,elderly patients with hepatocellular carcinoma,sorafenib or lenvatinib,not specified,progression-free survival and overall survival,retrospective observational study,False,Intervention is not immune checkpoint inhibitors and study design is not a randomized controlled trial.
63,63,systemic treatment-naive patients with unresectable hepatocellular carcinoma,tislelizumab plus lenvatinib,not specified,objective response rate,"multicenter, single-arm, phase 2 study",False,Study design is not a randomized controlled trial and comparison is not specified.
64,64,patients with initially unresectable hepatocellular carcinoma,lenvatinib combined with transcatheter arterial chemoembolization plus a PD-1 inhibitor,initial surgery,event-free survival and overall survival,retrospective study,False,Study design is not a randomized controlled trial.
65,65,patients with resectable hepatocellular carcinoma with macrovascular invasion,tislelizumab plus intensity modulated radiotherapy,not specified,overall response rate and overall survival,phase 2 trial,False,Study design is not a randomized controlled trial and comparison is not specified.
66,66,"patients with single, huge, resectable hepatocellular carcinoma","sequential TACE, camrelizumab, and apatinib",surgery alone,recurrence-free survival,"multi-center, open-label randomized phase 3 trial",False,Intervention includes but is not limited to immune checkpoint inhibitors.
67,67,patients with hepatocellular carcinoma after narrow-margin hepatectomy,radiotherapy or transarterial chemoembolization,not specified,overall survival and progression-free survival,single-center prospective randomized study,False,Intervention is not immune checkpoint inhibitors and comparison is not specified.
68,68,patients with hepatocellular carcinoma and colorectal liver metastasis,microwave ablation or radiofrequency ablation,not specified,"short-to-long diameter ratio of ablation zone, primary technical success, and local tumor progression",randomized phase 2 clinical trial,False,Intervention is not immune checkpoint inhibitors and comparison is not specified.
69,69,patients with recurrent hepatocellular carcinoma,radiofrequency ablation combined with toripalimab,radiofrequency ablation alone,recurrence free survival,not specified,False,Study design is not specified and intervention includes but is not limited to immune checkpoint inhibitors.
70,70,patients with HCC of BCLC stage A exceeding the Milan criteria or BCLC stage B,sintilimab plus DEB-TACE,not specified,"progression-free survival, objective response rate, pathologic response rate","prospective, phase II study",False,"Population and intervention match, but comparison and study design do not meet PICOS criteria."
71,71,patients with advanced HCC,radiotherapy combined with tislelizumab and anlotinib,not specified,"overall survival, progression-free survival",not specified,False,"Population and intervention partially match, but comparison and study design do not meet PICOS criteria."
72,72,patients with Child-Pugh A to B7 liver function,SBRT with dose optimization,conventional SBRT,"local control, toxicity",phase II clinical trial,False,"Population, intervention, and comparison match, but outcome and study design do not fully meet PICOS criteria."
73,73,HCC patients who underwent hepatectomy,postoperative adjuvant transarterial chemoembolization,no PA-TACE,"disease-free survival, overall survival",retrospective analysis,False,"Population, intervention, and comparison match, but study design does not meet PICOS criteria."
74,74,patients with early-stage HCC,machine learning model for treatment recommendations,not specified,survival rates,not specified,False,"Population and intervention partially match, but comparison and study design do not meet PICOS criteria."
75,75,patients with small malignant liver tumors,CEUS-CT/MRI fusion imaging-guided RFA,not specified,"tumor visibility, technical success, local tumor progression",prospective study,False,"Population and intervention match, but comparison and study design do not meet PICOS criteria."
76,76,BCLC early stage HCC patients with lesions 2-5 cm,adjuvant (super-)selective infusion of (166)Ho-MS after RFA,not specified,"target volume dose, local recurrences","multicenter, prospective dose-escalation study",False,"Population and intervention match, but comparison and study design do not meet PICOS criteria."
77,77,patients with unresectable HCC,atezolizumab and bevacizumab,not specified,"overall survival, time-to-progression, progression-free survival, objective response rate",observational study,False,"Population and intervention match, but comparison and study design do not meet PICOS criteria."
78,78,"patients with poor prognosis, localized HCC",pembrolizumab in conjunction with glass yttrium-90 (Y90) radioembolization,not specified,"6-month progression-free survival, time to progression, objective response rate, overall survival","open-label, single-arm multicenter, pilot study",False,"Population and intervention match, but comparison and study design do not meet PICOS criteria."
79,79,patients with intermediate-stage HCC,atezolizumab + bevacizumab prior to or in combination with TACE,not specified,"24-month survival rate, objective response rate, progression-free survival","multicenter, randomized phase II study",False,"Population and intervention match, but comparison and study design do not meet PICOS criteria."
80,80,patients with unresectable hepatocellular carcinoma,UCPVax vaccine combined with atezolizumab and bevacizumab,atezolizumab and bevacizumab without UCPVax,objective response rate at 6 months,multicenter randomized phase II study,True,"Matches PICOS criteria with specified population, intervention, comparison, outcome, and study design."
81,81,patients with cirrhosis and hepatocellular carcinoma,TARE with Iodine-131-lipiodol,TACE,objective tumor response and survival,prospective clinical trial,False,Does not match PICOS criteria as the intervention is not immune checkpoint inhibitors.
82,82,patients with unresectable hepatocellular carcinoma,camrelizumab combined with palliative SBRT,not specified,objective response rate and safety,phase 2 clinical trial,False,Does not match PICOS criteria as the comparison is not specified.
83,83,patients treated with TACE,not specified,not specified,diagnostic performance of CEUS Nonradiation TRA LI-RADS,retrospective observational study,False,Does not match PICOS criteria as the intervention and comparison are not specified.
84,84,patients with massive hepatocellular carcinoma,camrelizumab plus TACE,TACE alone,clinical efficacy and adverse events,prospective study,False,Does not match PICOS criteria as the study design is not a randomized controlled trial.
85,85,patients with MVI-positive HCC receiving marginal resection,postoperative adjuvant SBRT,surgery alone,disease-free survival and overall survival,single-centre randomised controlled trial,False,Does not match PICOS criteria as the intervention is not immune checkpoint inhibitors.
86,86,patients with HCC recurrence who underwent curative surgery for HBV-related HCC,sequential therapy with ropeginterferon alfa-2b and nivolumab,not specified,"safety, tolerability, and inhibitory activity",Phase I clinical trial,False,Does not match PICOS criteria as the comparison is not specified.
87,87,outpatient patients with HCC,not specified,not specified,status of nonadherence and influencing factors,prospective observational study,False,Does not match PICOS criteria as the intervention and comparison are not specified.
88,88,patients with advanced HCC in whom previous ICI therapy has failed,"SBRT, sintilimab and IBI305",not specified,objective response rate,"open-label, single-arm, single-centre, phase 2 trial",False,Does not match PICOS criteria as the comparison is not specified.
89,89,intermediate stage HCC patients,TACE plus sorafenib,TACE alone,"time-to-complete response, time-to-TACE progression, progression-free survival",randomized study,False,Does not match PICOS criteria as the intervention is not immune checkpoint inhibitors.
90,90,patients with advanced or unresectable hepatocellular carcinoma,nivolumab alone or nivolumab plus ipilimumab,nivolumab alone vs. nivolumab plus ipilimumab,"overall survival, progression-free survival, overall response rate",multicenter phase 1 randomized trial,False,"Intervention includes ICIs but comparison is between different ICI regimens, not against non-ICI or placebo."
91,91,patients with HBV-related HCC within the Milan criteria and with clinically significant PHT,partial hepatectomy,interventional treatment using ablation with or without pre-ablation TACE,"overall survival, recurrence-free survival",open-label randomized clinical trial,False,Intervention does not involve ICIs.
92,92,"adults with untreated, unresectable/metastatic HCC","BMS-986,205 in combination with nivolumab",not specified,"safety, tolerability, preliminary efficacy",Phase I/II study,False,No comparison against non-ICI or placebo is specified.
93,93,patients with unresectable hepatocellular carcinoma,DEB-TACE combined with apatinib,DEB-TACE monotherapy,"progression-free survival, overall survival, objective response rates, disease control rates","randomized, prospective, multicenter phase III trial",False,Intervention does not involve ICIs.
94,94,HCC patients with PVTT,DEB-TACE,conventional TACE,"progression-free survival, overall survival, incidence of adverse events",randomized controlled trial,False,Intervention does not involve ICIs.
95,95,patients diagnosed with stage I-III HCC treated with TACE,combination stereotactic body radiotherapy or radiofrequency ablation,no additional liver-directed modality,progression-free survival,retrospective observational study,False,Study design is not a randomized controlled trial and intervention does not involve ICIs.
96,96,advanced primary liver cancer patients with malignant ascites,intraperitoneal anti-PD-1 antibody,not specified,"safety, objective response rate, ascites control rate, overall survival",phase Ib study,False,No comparison against non-ICI or placebo is specified.
97,97,patients with a resectable single and small hepatitis B virus-related HCC predicted to have high risks of MVI,neoadjuvant intensity modulated radiation therapy,upfront surgery,"disease-free survival, overall survival, objective response rate",randomized trial,False,Intervention does not involve ICIs.
98,98,BCLC A patients with a solitary HCC from 4 to 7 cm,combination of TACE and SBRT,not specified,"best objective response rate, overall survival, progression-free survival",phase 2 trial,False,No comparison against non-ICI or placebo is specified.
99,99,patients with advanced ESCC and HCC,AL2846 in combination with an anti-PD-L1 antibody,not specified,"overall response rate, safety, progression-free survival, overall survival",phase 1b study,False,No comparison against non-ICI or placebo is specified.
100,100,patients with hepatocellular carcinoma,3'-deoxy-3'-(18)F-fluorothymidine PET,not specified,response to TACE,prospective study,False,"Population and intervention partially match, but comparison and study design do not meet PICOS criteria."
101,101,patients with small hepatocellular carcinoma,"three-channel, dual radiofrequency generator with separable clustered electrodes",not specified,local tumor progression and intrahepatic remote recurrence rates,prospective study,False,"Population and intervention partially match, but comparison and study design do not meet PICOS criteria."
102,102,hepatocellular carcinoma patients with inferior vena cava tumour thrombus,stereotactic body radiotherapy,not specified,local control and overall survival,observational retrospective study,False,"Population and intervention partially match, but comparison and study design do not meet PICOS criteria."
103,103,treatment-naïve patients with HCC,idarubicin-based transarterial chemoembolization,doxorubicin-based TACE,objective response rate,randomized controlled trial,True,"Fully matches PICOS criteria with specified population, intervention, comparison, outcome, and study design."
104,104,HR+/Her2- locally advanced breast cancer patients,drug-eluting bead-transarterial chemoembolization combined with systemic chemotherapy,systemic chemotherapy alone,overall response rate and pathological complete response,controlled study,False,"Population does not match; intervention, comparison, and outcome partially match, but study design does not meet PICOS criteria."
105,105,patients with HCC >3-<5 cm,combined therapy with conventional transarterial chemoembolization and microwave ablation,TACE or MWA alone,"complete response, recurrence rate, and overall survival rate",randomized controlled trial,True,"Fully matches PICOS criteria with specified population, intervention, comparison, outcome, and study design."
106,106,patients with hepatocellular carcinoma,transarterial chemoembolization,not specified,treatment forms and outcomes,retrospective observational study,False,"Population and intervention partially match, but comparison and study design do not meet PICOS criteria."
107,107,patients with advanced liver cancer,novel antisense oligonucleotide drug targeting human IGF-1R,not specified,tolerability and safety,dose-escalation trial,False,"Population and intervention partially match, but comparison and study design do not meet PICOS criteria."
108,108,participants with advanced HCC,TACE followed by HAIC with or without oral S-1,TACE followed by HAIC without oral S-1,progression-free survival and overall survival,randomized controlled trial,True,"Fully matches PICOS criteria with specified population, intervention, comparison, outcome, and study design."
109,109,patients with intermediate-stage hepatocellular carcinoma,pembrolizumab following TACE,not specified,safety and bioactivity,phase Ib study,False,"Population and intervention partially match, but comparison and study design do not meet PICOS criteria."
110,110,patients with hepatocellular carcinoma,not specified,not specified,prognosis prediction,not specified,False,"Intervention, comparison, and study design not specified; outcome does not match survival or response rate."
111,111,patients with liver cancer,microwave ablation,not specified,technical effectiveness and safety,not specified,False,Population not specifically hepatocellular carcinoma; intervention not ICIs; comparison and study design not specified.
112,112,patients with hepatocellular carcinoma,NAC and DEXA,placebo,prevention of PES and liver decompensation,randomized controlled trial,False,Intervention not ICIs; outcome does not match survival or response rate.
113,113,patients with hepatocellular carcinoma,PD-1 inhibitors,not specified,relapse-free survival,single-arm phase 2 trial,False,Comparison not specified; study design not randomized controlled trial.
114,114,patients with hepatocellular carcinoma,stereotactic body radiation therapy,not specified,local control and overall survival,prospective phase 2 trial,False,Intervention not ICIs; comparison not specified; study design not randomized controlled trial.
115,115,patients with hepatocellular carcinoma,liver transplantation,DCD vs DBD livers,"HCC recurrence, patient survival, and graft survival",cohort study,False,Intervention not ICIs; study design not randomized controlled trial.
116,116,patients with compensated cirrhosis,carvedilol,placebo,incidence of decompensated events and liver-related death,"randomized, double-blind, placebo-controlled, multicentre trial",False,Population not specifically hepatocellular carcinoma; intervention not ICIs.
117,117,patients with liver cancer,oxycodone vs fentanyl,not specified,perioperative pain management and side effects,not specified,False,Population not specifically hepatocellular carcinoma; intervention not ICIs; comparison and study design not specified.
118,118,patients with hepatocellular carcinoma and metastatic liver tumors,stereotactic RF ablation,not specified,technical efficacy and overall survival,retrospective observational study,False,Intervention not ICIs; comparison not specified; study design not randomized controlled trial.
119,119,patients with hepatocellular carcinoma,sunitinib plus doxorubicin-TACE,placebo,"bleeding or liver failure, safety, and survival outcomes","randomized, double-blind study",False,Intervention not ICIs; outcome does not match survival or response rate.
120,120,patients with advanced hepatocellular carcinoma,palliative stereotactic body radiation therapy (SBRT),not specified,"local control, overall survival, adverse events",observational retrospective study,False,Does not match PICOS criteria due to lack of specified comparison and not being a randomized controlled trial.
121,121,patients with hepatocellular carcinoma or metastatic colorectal cancer,Selective Internal radiation therapy with (90)Y resin microspheres,not specified,"overall survival, adverse events","multicenter, single-arm, prospective, observational study",False,Does not match PICOS criteria due to lack of specified comparison and not being a randomized controlled trial.
122,122,patients with unresectable hepatocellular carcinoma,drug-eluting beads transarterial chemoembolization (DEB-TACE),conventional transarterial chemoembolization (cTACE),"overall survival, progression-free survival, safety",randomized controlled trial,False,Does not match PICOS criteria as the intervention is not immune checkpoint inhibitors.
123,123,patients with hepatocellular carcinoma,ultrasonic radiomics model,not specified,recurrence and differentiation of HCC,retrospective study,False,Does not match PICOS criteria due to lack of specified comparison and intervention not being immune checkpoint inhibitors.
124,124,patients with hepatocellular carcinoma and portal vein tumor thrombus,radiotherapy prior to transcatheter arterial chemoembolization (RT + TACE),TACE followed with RT (TACE + RT),"overall survival, progression-free survival",randomized controlled trial,False,Does not match PICOS criteria as the intervention is not immune checkpoint inhibitors.
125,125,patients with hepatocellular carcinoma,immune checkpoint inhibitors (nivolumab and ipilimumab),not specified,antitumor response,virtual clinical trial using quantitative systems pharmacology model,False,Does not match PICOS criteria due to lack of specified comparison and not being a randomized controlled trial.
126,126,patients underwent liver transarterial chemoembolization,Digital variance angiography (DVA),digital subtraction angiography (DSA),"contrast-to-noise ratio, image quality",retrospective study,False,Does not match PICOS criteria due to population not being specifically hepatocellular carcinoma patients and intervention not being immune checkpoint inhibitors.
127,127,patients with advanced hepatocellular carcinoma,GT90001 plus nivolumab,not specified,"safety, anti-tumor activity",phase 1b/2 study,False,Does not match PICOS criteria due to lack of specified comparison and not being a randomized controlled trial.
128,128,patients with unresectable hepatocellular carcinomas,liver stereotactic body radiotherapy (SBRT),not specified,"local control rate, overall survival, toxicities",single-institution phase II study,False,Does not match PICOS criteria due to lack of specified comparison and intervention not being immune checkpoint inhibitors.
129,129,patients with metastatic non-small cell lung cancer,new systemic treatments,control arm treatments,"quality of life, progression-free survival, overall survival",phase III randomized controlled trials,False,Does not match PICOS criteria due to population not being hepatocellular carcinoma patients and intervention not being immune checkpoint inhibitors.
130,130,patients with unresectable hepatocellular carcinoma,TACE combined with TKI and camrelizumab,not specified,progression-free survival and objective response rate,not specified,False,"The study does not specify a comparison group without the studied ICIs or placebo, and the study design is not explicitly stated as a randomized controlled trial."
131,131,patients with unresectable HCC,TACE with dicycloplatin alone or plus epirubicin,epirubicin alone,"objective response rate, disease control rate, progression-free survival","randomized, open-label, phase II trial",False,"The intervention does not involve immune checkpoint inhibitors, and the study design is a phase II trial, not a randomized controlled trial as per PICOS criteria."
132,132,patients with unresectable hepatocellular carcinoma,DEB-TACE with doxorubicin-loaded CalliSpheres microspheres,cTACE with doxorubicin-lipiodol emulsion,"clinical response rate, overall survival, progression-free survival",randomized controlled trial,False,"The intervention does not involve immune checkpoint inhibitors, which is a key component of the target PICOS criteria."
133,133,advanced stage HCC patients,sorafenib and TACE,sorafenib alone,survival,not specified,False,"The intervention does not involve immune checkpoint inhibitors, and the study design is not explicitly stated as a randomized controlled trial."
134,134,patients with HCC,DEB-TACE,not specified,acute liver function deterioration,not specified,False,"The study focuses on predicting ALFD after DEB-TACE, not on immune checkpoint inhibitors or survival/response rates, and lacks a comparison group and randomized controlled trial design."
135,135,patients with PD-L1-positive advanced gastric/gastroesophageal junction cancer,pembrolizumab,paclitaxel,"overall survival, progression-free survival, objective response rate","randomized, controlled, phase III trial",False,"The population is not patients with hepatocellular carcinoma, and the intervention is not specifically compared to treatment without ICIs or placebo in the context of HCC."
136,136,HCC patients,SIRT and DEB-TACE,not specified,transplant-free survival,retrospective multicentre cohort study,False,"The study does not involve immune checkpoint inhibitors, lacks a comparison group without the studied intervention, and is not a randomized controlled trial."
137,137,patients with HCC tumors sized 3.5-7 cm,sorafenib prior to RFA,placebo prior to RFA,"size of ablation zone, RFA thermal parameters","randomized, double-blind, placebo-controlled phase II trial",False,"The intervention does not involve immune checkpoint inhibitors, and the outcomes are not survival rate or response rate."
138,138,patients with metastatic PDAC,ICI with SBRT,not specified,"safety, objective response",phase I study,False,"The population is not patients with hepatocellular carcinoma, and the study design is a phase I study, not a randomized controlled trial."
139,139,patients with unresectable early- and intermediate-stage HCC,tirapazamine in TACE,not specified,"safety, complete response rate","phase I, 3 + 3 dose-escalation study",False,"The intervention does not involve immune checkpoint inhibitors, and the study design is a phase I study, not a randomized controlled trial."
140,140,patients with hepatocellular carcinoma,yttrium-90 resin transarterial radioembolization,TACE-naïve participants,overall survival and imaging response,"prospective, observational study",False,Intervention is not immune checkpoint inhibitors and study design is not randomized controlled trial.
141,141,unresectable Barcelona Clinic Liver Cancer stage B HCC Child Pugh A patients,TACE followed by SBRT,TACE alone,"local control, progression free survival, overall survival",randomized controlled trial,False,Intervention is not immune checkpoint inhibitors.
142,142,patients with high-risk recurrence factors after curative resection of HCC,Cidan Capsule combined with TACE,TACE without Cidan Capsule,"disease-free survival, tumor recurrence rate, overall survival","multicenter, randomized controlled trial",False,Intervention is not immune checkpoint inhibitors.
143,143,patients with HCCs >3 cm,combination therapy using TACE with MWA,MWA monotherapy,"local tumor progression, tumor control rate, overall survival",two-arm retrospective observational study,False,Intervention is not immune checkpoint inhibitors and study design is not randomized controlled trial.
144,144,patients with HCC lesions at unusual regions,RFA under general anesthesia or local anesthesia plus intraoperative analgesia,not specified,"rate of tumor inactivation, pain score, complications",not specified,False,"Population, intervention, and study design do not match the criteria."
145,145,advanced PHC patients,TACE combined with radioactive iodine implantation therapy,TACE alone,"tumor lesion length, clinical effect, serum AFP, CT perfusion parameters",randomized controlled trial,False,Intervention is not immune checkpoint inhibitors.
146,146,patients with large or huge HCC,CBATO-TACE,cTACE,"progression-free survival, overall survival, treatment response, treatment-related adverse events",randomized controlled trial,False,Intervention is not immune checkpoint inhibitors.
147,147,patients with virologically suppressed HBV-compensated cirrhosis and small/medium EV,carvedilol plus NUC,NUC alone,"progression rate of EV, liver-related events",randomized controlled trial,False,Population and intervention do not match the criteria.
148,148,patients with intermediate-stage HCC beyond the Up-to-7 criteria,LEN-TACE sequential therapy,not specified,"resection rate, objective response rate, safety, curative resection rate, overall survival, recurrence-free survival","multicentre, single-arm, prospective clinical trial",False,Intervention is not immune checkpoint inhibitors and study design is not randomized controlled trial.
149,149,patients with HCC beyond the Milan criteria who underwent TACE after TIPS,TACE,not specified,overall survival,retrospective study,False,Intervention is not immune checkpoint inhibitors and study design is not randomized controlled trial.
150,150,patients with Barcelona Clinic Liver Cancer (BCLC) stage-B HCC,TACE combined with atezolizumab plus bevacizumab,not specified,"objective response rate, overall survival, disease control rate, progression-free survival, time-to-progression, safety","open-label, single-arm phase II clinical trial",False,"Population and intervention match, but there is no comparison group specified, and the study design is not a randomized controlled trial."
151,151,patients with early hepatocellular carcinoma,radiofrequency ablation,percutaneous ethanol injection,"cost-effectiveness, complete response rate, complication rate",prospective single-center randomized trial,False,"Population and study design match, but the intervention is not immune checkpoint inhibitors, and the outcomes do not include survival rate or response rate."
152,152,patients with locally advanced or metastatic HCC who were FGF19-positive,BLU-554 in combination with CS1001,not specified,"objective response rate, disease control rate, safety",Phase Ib/II trial,False,"Population and intervention partially match, but there is no comparison group specified, and the study design is not a randomized controlled trial."
153,153,patients with refractory MSS CLM,VB-111 and nivolumab,not specified,"overall response rate, safety/tolerability, median overall survival, progression-free survival",phase II study,False,"Population does not match (MSS CLM instead of HCC), and there is no comparison group specified."
154,154,patients with HCC in the caudate lobe,US-guided percutaneous microwave ablation,not specified,"efficacy, feasibility, tolerability, overall survival rates, progression-free survival",retrospective analysis,False,"Population matches, but the intervention is not immune checkpoint inhibitors, and there is no comparison group specified. The study design is not a randomized controlled trial."
155,155,patients with unresectable HCC,apatinib combined with IMRT,not specified,"maximum tolerated dose, objective response rate, disease control rate, progression-free survival, overall survival",dose-escalation design,False,"Population matches, but the intervention is not immune checkpoint inhibitors, and there is no comparison group specified. The study design is not a randomized controlled trial."
156,156,patients with intermediate stage of HCC after an incomplete response following TAE/TACE,SBRT,standard TAE/TACE,"1-year local control, progression-free survival, distant recurrence-free survival, overall survival, incidence of acute and late complications","single-center, prospective, randomized, controlled, parallel-group superiority trial",False,"Population and study design match, but the intervention is not immune checkpoint inhibitors, and the outcomes do not include survival rate or response rate."
157,157,HCC patients,TACE and HAIC,no other treatment,impact on liver function,not specified,False,"Population matches, but the intervention is not immune checkpoint inhibitors, and the outcomes do not include survival rate or response rate. The study design is not specified."
158,158,HCV-infected patients,sofosbuvir/velpatasvir or glecaprevir/pibrentasvir,not specified,"safety, sustained virological response",observational study,False,"Population does not match (HCV instead of HCC), and the intervention is not immune checkpoint inhibitors."
159,159,advanced HBV-HCC patients,HBV-TCR-T-cell immunotherapy,not specified,"safety, anti-tumor responses, overall survival","open-label, phase 1 dose-escalation study",False,"Population matches, but the intervention is not immune checkpoint inhibitors, and there is no comparison group specified. The study design is not a randomized controlled trial."
160,160,patients with hepatocellular carcinoma and portal vein tumor thrombus,TACE plus lenvatinib,TACE plus sorafenib,time-to-progression and objective response rate,randomized controlled trial,False,Intervention is not immune checkpoint inhibitors
161,161,advanced HCC patients with variceal bleeding,TIPS,endoscopic + β-blocker therapy,variceal rebleeding and overall survival,randomized controlled trial,False,Intervention is not immune checkpoint inhibitors
162,162,patients with metastatic colorectal cancer to the liver,IRI-HEP-TACE,not specified,overall survival and progression-free survival,prospective study,False,Population and intervention do not match criteria
163,163,treatment-naïve HBV-related decompensated patients,antiviral treatment,not specified,recompensation rate and further decompensation,retrospective multi-center study,False,Population and intervention do not match criteria
164,164,patients with liver cancer after TACE,individualized nutritional intervention,routine dietary intervention,nutritional status and liver function status,randomized controlled trial,False,Population and intervention do not match criteria
165,165,patients with advanced HCC,axitinib in combination with radiotherapy,not specified,maximum tolerated dose and overall response rate,phase I study,False,Intervention is not immune checkpoint inhibitors
166,166,patients with small HCC,PAAI,RFA,tumor response and survival rate,randomized trial,False,Population and intervention do not match criteria
167,167,patients with advanced HCC,SIRT+sorafenib,sorafenib alone,survival,randomized controlled trial,False,Intervention is not immune checkpoint inhibitors
168,168,HCC patients treated with ICIs,"continuation of ICI, treatment switching to TKIs, cessation of anticancer therapy",not specified,post-progression survival,not specified,True,Matches all PICOS criteria
169,169,patients with beyond-the-Milan criteria HCC,combination TACE and RFA therapy,TACE monotherapy,1-month tumour response and progression-free survival,randomized controlled trial,False,Intervention is not immune checkpoint inhibitors
170,170,patients with advanced HCC,galunisertib and ramucirumab,not specified,"safety, pharmacokinetics, antitumor efficacy","multicenter, open-label, phase 1b study",False,Does not specify comparison or focus on survival/response rate as primary outcomes.
171,171,patients with primary HCC,DEB TACE,not specified,"short term clinical efficacy, side effects",prospective study,False,Lacks comparison group and does not focus on survival/response rate as primary outcomes.
172,172,patients with advanced or metastatic HCC,itacitinib,not specified,safety and efficacy,Phase Ib study,False,No comparison group and outcomes not focused on survival/response rate.
173,173,patients with untreated advanced HCC,anlotinib alone or combined with S-1,anlotinib vs. anlotinib+S-1,"objective response rate, disease control rate, progression-free survival, overall survival",randomized controlled trial,True,Matches all PICOS criteria including randomized controlled trial design and survival/response outcomes.
174,174,liver transplanted patients with HBV-HCC recurrence,HBV-TCR engineered T cells,not specified,"clinical efficacy, polyfunctionality of TCR-T cells",not specified,False,Lacks comparison group and study design not specified.
175,175,patients with HCC previously treated with MTAs,atezolizumab plus bevacizumab,not specified,treatment effect on HCC,not specified,False,No comparison group and study design not specified.
176,176,HCC Egyptian patients,TACE using doxorubicin and lipiodol,not specified,response to TACE,prospective cohort study,False,Lacks comparison group and does not focus on survival/response rate as primary outcomes.
177,177,hepatocellular carcinoma patients,x-ray images of radio-opaque chemoembolisation deposits,not specified,feasibility of real-time image-guided radiation therapy,observational study,False,No comparison group and outcomes not focused on survival/response rate.
178,178,CNLC-IIIb stage HCC patients,hepatectomy with apatinib and camrelizumab,not specified,patient mortality,multicentre phase II trial,False,Lacks comparison group and outcomes not focused on survival/response rate.
179,179,HCC patients with PVI,various treatment modalities,not specified,patterns of treatment modalities and outcomes,"prospective, observational, multicenter, cohort study",False,No comparison group and outcomes not focused on survival/response rate.
180,180,patients with primary hepatocellular carcinoma,DEB-TACE,not specified,clinical death and 6-month survival rate,retrospective study,False,"Does not match PICOS criteria: intervention is not ICIs, no comparison with ICIs or placebo, study design is not RCT."
181,181,patients with operable or radiofrequency ablation-treatable primary HCC,image-guided proton therapy,not specified,"overall survival, local control, adverse events, quality of life",phase 2 study,False,"Does not match PICOS criteria: intervention is not ICIs, no comparison with ICIs or placebo, study design is not RCT."
182,182,HCC patients with portal vein tumour thrombus,preoperative SBRT and surgery followed by HAIC,not specified,"pathology of irradiated PVTT specimen, SBRT-related acute toxicity",prospective study,False,"Does not match PICOS criteria: intervention is not ICIs, no comparison with ICIs or placebo, study design is not RCT."
183,183,patients with unresectable HCC,SBRT,not specified,"treatment-related severe toxicity, local control, progression-free survival, overall survival",multicenter phase 2 trial,False,"Does not match PICOS criteria: intervention is not ICIs, no comparison with ICIs or placebo, study design is not RCT."
184,184,patients with HCC,multipolar RFA system,not specified,therapeutic efficacy and safety,retrospective cohort study,False,"Does not match PICOS criteria: intervention is not ICIs, no comparison with ICIs or placebo, study design is not RCT."
185,185,patients with HCC undergoing TACE,real-time radiation dosimetry,not specified,occupational radiation dose,retrospective observational study,False,"Does not match PICOS criteria: intervention is not ICIs, no comparison with ICIs or placebo, study design is not RCT."
186,186,patients with unresectable HCC,TACE combined with PD-1 inhibitors plus lenvatinib,PD-1 inhibitors plus lenvatinib,"objective response rate, overall survival, progression-free survival, adverse events","observational, retrospective, cohort study",False,"Does not match PICOS criteria: intervention includes TACE, not solely ICIs, study design is not RCT."
187,187,HCC patients undergoing hepatectomies,hepatectomy,not specified,"overall survival, liver-specific survival, disease-free survival",retrospective study,False,"Does not match PICOS criteria: intervention is not ICIs, no comparison with ICIs or placebo, study design is not RCT."
188,188,HCC patients with BDTT,surgery,not specified,patterns and kinetics of recurrence,retrospective study,False,"Does not match PICOS criteria: intervention is not ICIs, no comparison with ICIs or placebo, study design is not RCT."
189,189,patients with advanced HCC,colchicine dosage schedule,sorafenib,efficiency and safety,phase IIa trial,False,"Does not match PICOS criteria: intervention is not ICIs, comparison is not with ICIs or placebo, study design is not RCT."
190,190,HCC patients within Milan Criteria,platelet lysates after RFA,platelet lysates before RFA,"proliferation, migration, invasion, and vasculogenic mimicry of HCC cells",not specified,False,Study does not match PICOS criteria as it lacks a randomized controlled trial design and does not focus on immune checkpoint inhibitors or survival/response rates.
191,191,"patients with liver, lung, and kidney tumors",high-power MWA,not specified,"technical success, safety, and effectiveness",retrospective observational study,False,Study does not match PICOS criteria as it does not focus on hepatocellular carcinoma patients treated with immune checkpoint inhibitors or compare with a control group without ICIs.
192,192,patients with HCC,DSM-RFA,SSM-RFA,"ablation zone size, complication rate, technique efficacy, and 2-year clinical outcomes",randomized controlled trial,False,Study does not match PICOS criteria as it focuses on radiofrequency ablation techniques rather than immune checkpoint inhibitors and does not specify survival or response rates as outcomes.
193,193,patients with HCC suitable for local ablation,MWA,RFA,"treatment-related morbidity, overall and disease-free survivals",randomized controlled trial,False,Study does not match PICOS criteria as it compares MWA and RFA rather than focusing on immune checkpoint inhibitors and does not specify survival or response rates as primary outcomes.
194,194,patients with hepatocellular carcinoma undergoing TACE,preoperative interviews and prospective nursing,routine nursing care,"heart rate, blood pressure, mood changes, pain, satisfaction, and complications",randomized controlled trial,False,Study does not match PICOS criteria as it focuses on nursing interventions rather than immune checkpoint inhibitors and does not specify survival or response rates as outcomes.
195,195,patients with small HCC,novel electrode system for RFA,not specified,technical efficacy and complications,prospective clinical trial,False,Study does not match PICOS criteria as it focuses on a novel RFA electrode system rather than immune checkpoint inhibitors and does not specify survival or response rates as outcomes.
196,196,patients with HBV-related primary liver cancer,TACE,not specified,severe abdominal pain post-TACE,randomized controlled trial,False,Study does not match PICOS criteria as it focuses on predicting severe abdominal pain post-TACE rather than evaluating immune checkpoint inhibitors or survival/response rates.
197,197,HCC patients and healthy volunteers,lncRNA expression analysis,not specified,lncRNA expression levels and their correlation with HCC,not specified,False,Study does not match PICOS criteria as it focuses on lncRNA expression in HCC rather than evaluating immune checkpoint inhibitors or survival/response rates.
198,198,HCC patients on the waiting list for liver transplantation,TACE,no TACE,intraoperative hepatic artery interventions and postoperative hepatic artery complications,propensity score-matched cohort study,False,Study does not match PICOS criteria as it focuses on TACE's impact on hepatic artery complications rather than evaluating immune checkpoint inhibitors or survival/response rates.
199,199,patients with liver cancer,RFA,not specified,relapse-free survival and overall survival,randomized controlled trial,False,Study does not match PICOS criteria as it focuses on the AFP ratio's prognostic value post-RFA rather than evaluating immune checkpoint inhibitors or comparing with a control group without ICIs.
200,200,patients with hepatocellular carcinoma,"RFA, TACE, TARE, Sorafenib",not specified,"recurrence-free rates, survival rates",retrospective observational study,False,"Does not match PICOS criteria due to lack of immune checkpoint inhibitors as intervention, no specified comparison group, and not a randomized controlled trial."
201,201,HCC patients resistant to TACE with doxorubicin,TACE with bleomycin,TACE with doxorubicin,"median progression-free survival, median overall survival",randomized controlled trial,False,Does not match PICOS criteria as the intervention is not immune checkpoint inhibitors.
202,202,patients with hepatocellular carcinoma,transarterial chemoembolization (TACE),not specified,"progression-free survival, TACE treatment response",prospective single-center observational study,False,Does not match PICOS criteria due to lack of immune checkpoint inhibitors as intervention and not a randomized controlled trial.
203,203,patients with gastroesophageal junction cancer and hepatic metastasis,transarterial infusion chemotherapy plus microsphere embolization,transarterial infusion chemotherapy,survival rates,randomized controlled trial,False,Does not match PICOS criteria as the population is not solely hepatocellular carcinoma and the intervention is not immune checkpoint inhibitors.
204,204,patients with biliary tract cancers,atezolizumab plus cobimetinib,atezolizumab monotherapy,progression-free survival,open-label phase II study,False,Does not match PICOS criteria as the population is not hepatocellular carcinoma.
205,205,patients with advanced hepatocellular carcinoma,cabozantinib plus atezolizumab,not specified,not specified,not specified,False,"Does not fully match PICOS criteria due to lack of specified comparison group, outcomes, and study design."
206,206,patients with advanced/metastatic solid tumors,CS1002 plus CS1003,not specified,objective response rates,phase 1 study,False,Does not match PICOS criteria as the population is not solely hepatocellular carcinoma and lacks a specified comparison group.
207,207,patients with liver tumours,microwave ablation with deep neuromuscular blockade,microwave ablation with moderate neuromuscular blockade,"liver excursion, performance scores, patient satisfaction, complications",not specified,False,Does not match PICOS criteria as the intervention is not immune checkpoint inhibitors and the population is not solely hepatocellular carcinoma.
208,208,patients with hepatocellular carcinoma,TACE with low dose doxorubicin,TACE with high dose doxorubicin,"post-embolisation syndrome, overall survival",randomized controlled trial,False,Does not match PICOS criteria as the intervention is not immune checkpoint inhibitors.
209,209,patients with early-stage hepatocellular carcinoma,holmium-166 microspheres after RFA,not specified,"biodistribution of holmium-166, toxicity, local recurrence, disease-free and overall survival","multicentre, prospective, dose-escalation study",False,Does not match PICOS criteria as the intervention is not immune checkpoint inhibitors and lacks a specified comparison group.
210,210,patients with hepatocellular carcinoma,neoadjuvant SBRT plus PD-1 (tislelizumab),not specified,"delay of surgery, tumour response, safety, disease-free survival, overall survival",phase Ib clinical trial,False,"No comparison group specified, not a randomized controlled trial"
211,211,patients with hepatocellular carcinoma treated with DEB-TACE,not specified,not specified,overall survival,"observational, retrospective, unicentric study",False,"No intervention or comparison specified, not a randomized controlled trial"
212,212,patients referred for TACE,pre-TACE 3D CT angiography,DSA,detection of HCC feeding vessels,prospective study,False,"Population not specifically hepatocellular carcinoma, not a randomized controlled trial"
213,213,patients undergoing TACE for HCC,transradial access (TRA),transfemoral access (TFA),"patient satisfaction, procedural variables, safety",randomized controlled trial,False,"Intervention not immune checkpoint inhibitors, outcome not survival or response rate"
214,214,patients with unresectable hepatocellular carcinoma,"lenvatinib, programmed death-1 inhibitors plus TACE",not specified,"overall survival, progression-free survival, early tumor shrinkage",prospective observational study,False,"No comparison group specified, not a randomized controlled trial"
215,215,patients with hepatocellular carcinoma contraindicated for hepatectomy and RFA,HIFU alone or combined with TACE,not specified,"local control rate, progression-free survival, overall survival",not specified,False,"No comparison group specified, study design not specified"
216,216,patients with CRLM,TACE with DSM or lipiodol,cTACE vs DSM-TACE,"tumor response, survival","prospective, randomized, single-center trial",False,"Population not hepatocellular carcinoma, outcome not survival or response rate"
217,217,dogs with nonresectable HC,DEB-TACE,not specified,"tumor responses, complications, survival","prospective, single-arm clinical trial",False,"Population not human, no comparison group specified"
218,218,patients with small HCCs,SBRT,not specified,"local control rate, overall survival","phase II, single-arm clinical trial",False,"No comparison group specified, not a randomized controlled trial"
219,219,patients with unresectable HCC,atezolizumab + bevacizumab,sorafenib,"objective response rate, depth and duration of response",phase III trial,True,"Matches all PICOS criteria: population, intervention, comparison, outcome, and study design"
220,220,patients with unresectable hepatocellular carcinoma,TACE combined with (131)I-metuximab,TACE alone,overall tumor recurrence and overall survival,"prospective nonrandomized, multicenter clinical trial",False,Study design is not a randomized controlled trial.
221,221,dogs with nonresectable hepatic carcinoma,drug-eluting bead transarterial-chemoembolization (DEB-TACE),not specified,median survival time,"prospective, single-arm clinical trial",False,"Population is not human, and study design is not a randomized controlled trial."
222,222,patients with primary liver cancer (PLC),Fuzheng Jiedu Xiaoji formula (FJXF) plus TACE,TACE alone,"disease control rate, liver biochemistry, liver function index, and multidrug resistance-associated indicators",randomized controlled trial,False,Intervention does not involve immune checkpoint inhibitors.
223,223,patients with hepatocellular carcinoma who underwent cTACE,repeated cTACE,not specified,median overall survival,retrospective study with random assignment into training and validation cohorts,False,"Intervention does not involve immune checkpoint inhibitors, and study design is not a randomized controlled trial."
224,224,HCC patients with portal vein tumor thrombus (PVTT),"liver resection, TACE, or sorafenib",not specified,overall survival,retrospective study with random division into training and internal validation cohorts,False,"Intervention does not involve immune checkpoint inhibitors, and study design is not a randomized controlled trial."
225,225,HCC patients with portal vein tumor thrombus (PVTT),Gamma knife radiosurgery (GKR) versus TACE,TACE,overall survival,retrospective study with propensity score matching analysis,False,"Intervention does not involve immune checkpoint inhibitors, and study design is not a randomized controlled trial."
226,226,HCC patients with low platelet counts,Lusutrombopag administration before RFA,not specified,PLT count elevation and prevention of PLT transfusions,not specified,False,"Intervention does not involve immune checkpoint inhibitors, and study design is not a randomized controlled trial."
227,227,patients with unresectable hepatocellular carcinoma undergoing TACE,"celecoxib, parecoxib, or controlled-release oxycodone",not specified,"pain scores, pain intensity, and adverse events","prospective, randomized, paralleled trial",False,Intervention does not involve immune checkpoint inhibitors.
228,228,adults with intermediate-stage HCC,TACE with two different IDA doses,not specified,"PK, antitumour effects, safety, treatment response, and survival",single-centre clinical trial,False,"Intervention does not involve immune checkpoint inhibitors, and study design is not a randomized controlled trial."
229,229,early non-resectable patients with HCC,LMWA and TACE,PRFA,overall survival and HCC-related death,retrospective multicenter observational study,False,"Intervention does not involve immune checkpoint inhibitors, and study design is not a randomized controlled trial."
230,230,patients with stage B or C liver cancer,early percutaneous transhepatic varices embolization (PTVE),control group without PTVE,"initial and recurrence rates of hemorrhage, liver function recovery, TACE frequency, and tumor control",retrospective study,False,"Population does not specifically mention hepatocellular carcinoma, intervention is not ICIs, and study design is not a randomized controlled trial."
231,231,patients with hepatocellular carcinoma,balloon-occluded alternate infusions of cisplatin and gelatin particles in transarterial chemoembolization,not specified,safety and objective response rate,multicenter prospective study,False,"Intervention is not ICIs, and study design is not a randomized controlled trial."
232,232,patients with standard chemotherapy refractory mismatch repair proficient metastatic colorectal cancer,pexastimogene devacirepvec plus durvalumab with and without tremelimumab,not specified,"safety, feasibility, progression-free survival, and overall survival",phase I/II trial,False,"Population is not hepatocellular carcinoma, and study design is not a randomized controlled trial."
233,233,patients with advanced digestive tract cancer including hepatocellular carcinoma,PD-1 inhibitors plus antiangiogenic agents,not specified,response and survival,observational retrospective study,False,Study design is not a randomized controlled trial.
234,234,patients with malignant hepatic lesions,radiofrequency ablation,historical control group,accuracy and clinical integrability of a simulation tool,prospective multicenter trial,False,"Population is not specifically hepatocellular carcinoma, intervention is not ICIs, and study design is not a randomized controlled trial."
235,235,patients with advanced hepatocellular carcinoma positive for hepatitis B virus,PHY906 and capecitabine combination,not specified,"6-month survival rate, progression-free survival, overall survival, disease control rate, and safety","open-label, phase II safety and efficacy clinical trial",False,"Intervention is not ICIs, and study design is not a randomized controlled trial."
236,236,patients with HCC at BCLC substage B2,lenvatinib,not specified,"overall survival, progression-free survival, and objective response rates",prospective observational study,False,"Intervention is not ICIs, and study design is not a randomized controlled trial."
237,237,patients with advanced hepatocellular carcinoma,ultrasound-guided microwave ablation,not specified,"overall survival rate, objective tumor remission rate, serum indices, and incidence of adverse effects",retrospective analysis,False,"Intervention is not ICIs, and study design is not a randomized controlled trial."
238,238,patients with unresectable HCC,DEM-TACE vs c-TACE,c-TACE,"12- and 24-month survival, postembolization syndrome, and severe adverse events",randomized study,False,Intervention is not ICIs.
239,239,patients who have undergone initial hepatectomy for HCC with risk factors for recurrence,peripheral blood CD34(+) stem cell-derived NK cell infusion,not specified,"safety assessment, survival, effect of immune response, and clinical laboratory test results","open-label, single-arm, single-centre phase I study",False,"Intervention is not ICIs, and study design is not a randomized controlled trial."
240,240,patients with HCC,single-fraction SBRT followed by TACE,not specified,"overall response rate, clinical benefit rate, survival rates",prospective phase 1 trial,False,"Population and intervention match, but no comparison group specified and study design is not a randomized controlled trial."
241,241,patients with unresectable HCC,atezolizumab with/without Roche DPM Module,with/without Roche DPM Module,"health outcomes, healthcare resource usage","interventional, open-label, multicountry platform study",False,"Population and intervention match, but outcomes do not focus on survival or response rate, and study design is not a randomized controlled trial."
242,242,HCC patients,not specified,not specified,"prognostic prediction, immunotherapeutic strategies",not specified,False,"No specific intervention or comparison group mentioned, and outcomes do not directly relate to survival or response rate."
243,243,advanced HCC patients,PEG-BCT-100 with chemotherapy,not specified,"safety, efficacy, survival rates",single centre phase 1 trial,False,"Population and intervention match, but no comparison group specified and study design is not a randomized controlled trial."
244,244,HCC patients with PVTT,SBRT with/without sorafenib,SBRT with sorafenib vs SBRT alone,"response rate, progression-free survival, overall survival",retrospective analysis,False,"Population, intervention, and comparison match, but study design is not a randomized controlled trial."
245,245,patients with HCC,isatuximab plus atezolizumab,not specified,"safety, activity, progression-free survival",phase I/II study,False,"Population and intervention match, but no comparison group specified and study design is not a randomized controlled trial."
246,246,patients with unresectable HCC after TACE failure,TAE therapy with/without iNKT cell infusion,TAE with iNKT vs TAE alone,"progression-free survival, overall survival, response rate","open-label, randomized, controlled trial",True,"Population, intervention, comparison, outcomes, and study design all match the PICOS criteria."
247,247,HCC patients and control cohorts,HCC EV purification system,not specified,early detection of HCC,not specified,False,"No specific intervention or comparison group mentioned, and outcomes do not directly relate to survival or response rate."
248,248,advanced HCC patients with ECOG 1,TACE,not specified,overall survival,nationwide multicenter observational study,False,"Population and intervention match, but no comparison group specified and study design is not a randomized controlled trial."
249,249,patients with BCLC stage A HCC,TACE,CR group vs non-CR group,overall survival,not specified,False,"Population and intervention match, but study design is not a randomized controlled trial."
250,250,patients with primary hepatocellular carcinoma,not specified,not specified,tumor-free survival and overall survival rates,not specified,False,Intervention and comparison not specified; study design not randomized controlled trial
251,251,patients with HCC and portal vein invasion,sorafenib plus TACE,not specified,survival time,observational study,False,Comparison not specified; study design not randomized controlled trial
252,252,patients with primary liver cancer,TACE combined with HIFU,TACE alone,3-year survival rate,not specified,False,Study design not randomized controlled trial
253,253,patients with advanced HCC,peptide cocktail vaccines,not specified,disease control rate,Phase I studies,False,Comparison not specified; study design not randomized controlled trial
254,254,hepatocellular carcinoma patients,stereotactic body radiotherapy,different BED schedules,"local control rates, overall survival rates, progression-free survival rates",randomized controlled trial,False,Intervention not immune checkpoint inhibitors
255,255,patients with primary and secondary hepatic malignancies,TACE,not specified,overall survival,not specified,False,Intervention not immune checkpoint inhibitors; comparison and study design not specified
256,256,HCC patients with microvascular invasion,TACE combined with targeted nanoparticle delivery system for sorafenib,TACE and non-nano drug delivery system,disease control rate,not specified,False,Intervention not immune checkpoint inhibitors; study design not randomized controlled trial
257,257,patients with HCC,GPC3 peptide vaccine,surgery only,disease-free survival and overall survival,phase II trial,False,Intervention not immune checkpoint inhibitors; study design not randomized controlled trial
258,258,patients with advanced primary liver cancer,camrelizumab with apatinib,not specified,"objective response rate, progression-free survival, overall survival",phase Ib/II trial,False,Comparison not specified; study design not randomized controlled trial
259,259,patients with primary carcinoma of the liver,TACE in combination with lobaplatin,TACE with cisplatin,efficacy and incidence rates of adverse events,not specified,False,Intervention not immune checkpoint inhibitors; study design not randomized controlled trial
260,260,patients with hepatocellular carcinoma (HCC) or refractory renal cell carcinomas (RCC),Sorafenib combined with evofosfamide,not specified,maximum tolerated dose and recommended phase II dose,phase IB 3 + 3 design,False,"Population includes RCC patients, not exclusively HCC. Intervention is not ICIs. No comparison group specified. Outcome is not survival or response rate. Study design is not RCT."
261,261,unresectable hepatocellular carcinoma (HCC) patients,TACE using CalliSpheres beads loading with arsenic trioxide,conventional TACE with ATO,"treatment response, progression-free survival, overall survival",not specified,False,Intervention is not ICIs. Study design is not specified as RCT.
262,262,patients with liver disease,liver surgery and ablative techniques,not specified,not specified,observational retrospective analysis,False,Population is not exclusively HCC. Intervention is not ICIs. No comparison group specified. Outcome not specified. Study design is not RCT.
263,263,patients with HCC in BCLC-stage-B,cTACE using Lipiodol-only vs. Lipiodol combined with degradable starch microspheres,cTACE with Lipiodol-only,"tumor response, survival time",prospective randomized trial,False,Intervention is not ICIs. Study design is RCT but intervention does not match.
264,264,patients with unresectable HCC (BCLC-B),TACE vs. TACE plus RFA,TACE alone,"quality of life, tumor therapy response",not specified,False,Intervention is not ICIs. Study design is not specified as RCT.
265,265,patients with liver tumor,pre-emptive erector spinae plane block,control group without ESPB,"opioid consumption, pain scores",randomized controlled trial,False,Population is not exclusively HCC. Intervention is not ICIs. Outcome is not survival or response rate.
266,266,patients with small hepatocellular carcinomas (HCC),no-touch (NT) radiofrequency ablation vs. conventional RFA,conventional RFA,"local tumor progression rate, technical efficacy, complications",prospective randomized controlled study,False,Intervention is not ICIs. Study design is RCT but intervention does not match.
267,267,patients with hepatocellular cancer (HCC),nivolumab/ipilimumab combination,not specified,"safety, tolerability, objective response rate, pathologic response rates",phase Ib study,False,Intervention matches ICIs but comparison group is not specified. Study design is not RCT.
268,268,patients with HCC,gadoxetic acid-enhanced MRI,not specified,"CD8 cell density, PD-L1 expression, objective response to immunotherapy",not specified,False,Intervention is not ICIs. No comparison group specified. Study design is not specified as RCT.
269,269,"subjects with cirrhosis and hypervascular, non-malignant intrahepatic nodules",not specified,not specified,transformation to hepatocellular carcinoma (HCC),retrospective observational study,False,Population is not exclusively HCC. Intervention is not specified. No comparison group specified. Study design is not RCT.
270,270,patients undergoing DEE-TACE for hepatocellular carcinoma,hepatic hilar and celiac plexus nerve blocks,"standard intraprocedural local anesthetic, intra-arterial lidocaine, and intravenous analgesia","pain, patient satisfaction, adverse events, and hospital stay","prospective, randomized trial",False,"Population and study design match, but intervention and outcome do not match the target criteria."
271,271,"patients with advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma",ramucirumab plus durvalumab,not specified,safety and preliminary efficacy,"phase Ia/b single-arm, non-randomised, multi-cohort study",False,"Population and intervention partially match, but comparison, outcome, and study design do not match the target criteria."
272,272,patients with recurrent HCC after locoregional treatment,bipolar radiofrequency ablation using twin internally cooled wet electrodes,switching monopolar RFA using separable clustered electrodes,"minimum diameter of the ablation zone per unit ablation time, complication rate, technical success and technique efficacy, and clinical outcomes","single-center, two-arm, parallel-group, randomized controlled study",False,"Population, comparison, and study design match, but intervention and outcome do not match the target criteria."
273,273,patients with unresectable hepatocellular carcinoma complicating hepatitis C virus-related cirrhosis,Conventional transarterial chemoembolization versus drug-eluting beads-TACE,not specified,"serum vascular endothelial growth factor levels, response to therapy, and tumor recurrence",not specified,False,"Population and intervention partially match, but comparison, outcome, and study design do not match the target criteria."
274,274,HCC patients in South Korea,sorafenib,not specified,"characteristics, treatment patterns, and outcomes","population-based retrospective, single-arm, observational study",False,"Population and intervention partially match, but comparison, outcome, and study design do not match the target criteria."
275,275,patients with stage III-IV primary lung cancer,DEB-TACE with pirarubicin-loaded CB,not specified,safety and efficacy,not specified,False,"Population does not match, and intervention, comparison, outcome, and study design do not match the target criteria."
276,276,patients with hepatocellular carcinoma,T cell-based immunotherapy targeting AFP,not specified,efficacy and safety profile of TCRs,not specified,False,"Population and intervention partially match, but comparison, outcome, and study design do not match the target criteria."
277,277,Chinese hepatocellular carcinoma patients,DEB-TACE,not specified,"efficacy, safety, and prognostic factors for treatment response and survival",prospective study,False,"Population and intervention partially match, but comparison, outcome, and study design do not match the target criteria."
278,278,patients with hepatocellular carcinoma,autologous invariant natural killer T cells,not specified,"safety, tolerability, and antitumor activity",phase I study,False,"Population and intervention partially match, but comparison, outcome, and study design do not match the target criteria."
279,279,patients with resectable HCC of stages II-IVa,HSP70 mRNA-transfected dendritic cell therapy,not specified,"safety, efficacy, disease-free survival, and overall survival",phase I/II randomized controlled clinical trial,False,"Population and study design partially match, but intervention, comparison, and outcome do not match the target criteria."
280,280,pediatric HB patients,HIFU combined with TACE,TACE alone,"survival rate, immune function, treatment side effects, clinical efficacy",comparative study,False,"Population is pediatric HB patients, not hepatocellular carcinoma. Study design is comparative, not randomized controlled trial."
281,281,patients with HCC or metastatic liver cancers,TACE,not specified,"MIF serum concentrations, overall survival",observational study,False,"Intervention is TACE, not immune checkpoint inhibitors. Study design is observational, not randomized controlled trial."
282,282,cirrhotic patients with HCC,DP-CBCT,pre-procedural SLIM,diagnostic accuracy,retrospective observational study,False,"Intervention is diagnostic imaging, not immune checkpoint inhibitors. Study design is retrospective observational, not randomized controlled trial."
283,283,patients with resected stage IIA-IV melanoma,vaccine comprising phosphorylated peptides,not specified,"safety, immunogenicity",clinical trial,False,"Population is melanoma patients, not hepatocellular carcinoma. Intervention is a vaccine, not immune checkpoint inhibitors."
284,284,patients with HCC following initial curative-intent resection or ablation,not specified,not specified,"overall survival, recurrence",retrospective observational study,False,"Intervention not specified. Study design is retrospective observational, not randomized controlled trial."
286,286,liver cancer patients,not specified,not specified,overall survival,observational study,False,"Intervention not specified. Study design is observational, not randomized controlled trial."
287,287,UICC7 Stage IIIA and IIIB potentially resectable HCC patients,preoperative chemotherapy,upfront resection,overall survival,phase II clinical trial,False,"Intervention is preoperative chemotherapy, not immune checkpoint inhibitors. Study design is phase II clinical trial, not randomized controlled trial."
288,288,patients with HCC,IRE,RFA,"progress-free survival, overall survival",randomized controlled clinical trial,False,"Intervention is IRE, not immune checkpoint inhibitors. Study design matches but intervention does not."
289,289,patients with advanced HCC,apatinib plus TACE,not specified,"overall survival, time to progression",observational study,False,"Intervention is apatinib plus TACE, not immune checkpoint inhibitors. Study design is observational, not randomized controlled trial."
285,285,not applicable,not applicable,not applicable,not applicable,not applicable,False,Abstract too short or empty
290,290,patients with advanced hepatocellular carcinoma,molecularly targeted agent (MTA) administration,not specified,overall survival and changes in CRP and ALBI scores,retrospective study,False,Does not match PICOS criteria due to lack of specified comparison and not being a randomized controlled trial.
291,291,patients with hepatocellular carcinoma,transarterial chemoembolization (TACE) via different access methods,different patients' positions via transradial access (TRA) or transfemoral access (TFA),radiation dose received by the operator,randomized controlled trial,False,Does not match PICOS criteria as the outcome is not survival rate or response rate.
292,292,patients with liver cancer undergoing transarterial chemoembolisation (TACE),modular multimodal hospital-home chain physical activity rehabilitation programme (3M2H-PARP),standard care,"liver frailty index, Functional Assessment of Cancer Therapy-Hepatobiliary subscale, Cancer Fatigue Scale, Pittsburgh Sleep Quality Index, Hospital Anxiety and Depression Scale and physical activity level",randomized controlled trial,False,Does not match PICOS criteria as the outcome is not survival rate or response rate.
293,293,patients with unresectable hepatocellular carcinoma,TACE with cisplatin,TACE with epirubicin,overall survival,randomized controlled trial,True,"Matches PICOS criteria as it includes the specified population, intervention, comparison, outcome, and study design."
294,294,patients with hepatoblastomas,surgical resection,not specified,overall survival,retrospective study,False,Does not match PICOS criteria due to lack of specified comparison and not being a randomized controlled trial.
295,295,patients with hepatocellular carcinoma,transradial access versus transfemoral access in conventional transarterial chemoembolization (c-TACE),right femoral access vs radial access,"operators radiations exposure, patients comfort, technical success and vascular access complications",randomized controlled trial,False,Does not match PICOS criteria as the outcome is not survival rate or response rate.
296,296,patients with early stage hepatocellular carcinoma who had undergone curative resection,not specified,not specified,recurrence rate,prospective study,False,"Does not match PICOS criteria due to lack of specified intervention and comparison, and not being a randomized controlled trial."
297,297,outpatients at an academic tertiary care centre,2019 EULAR/American College of Rheumatology (ACR) classification criteria for systemic lupus erythematosus (SLE),1997 ACR and the 2012 Systemic Lupus International Collaborating Clinics criteria,sensitivity and specificity of the 2019 criteria,prospective and retrospective observational cohort study,False,Does not match PICOS criteria as the population is not patients with hepatocellular carcinoma and the outcome is not survival rate or response rate.
298,298,patients with compensated HBV cirrhosis,entecavir-based therapy,not specified,health-related quality of life (HRQoL),randomized controlled trial,False,Does not match PICOS criteria as the outcome is not survival rate or response rate.
299,299,survivors of UGI and HPB cancer,12-week multidisciplinary rehabilitation programme,standard survivorship care,"cardiorespiratory fitness, physical function, body composition, nutritional status, HRQOL, and fatigue",randomized controlled trial,False,Does not match PICOS criteria as the population is not patients with hepatocellular carcinoma and the outcome is not survival rate or response rate.
300,300,patients with NAFLD,not specified,not specified,not specified,observational cohort study,False,Population does not match; study design is not RCT
301,301,HCC patients after TACE,Chaihu Guizhi decoction,placebo,incidence of PES,randomized controlled trial,False,Population and intervention do not match PICOS criteria
303,303,patients with sCR,watchful waiting,liver transplantation,overall and recurrence-free survival,retrospective analysis,False,Study design is not RCT; intervention does not match
304,304,HCC patients previously treated with sorafenib,pembrolizumab,placebo,HRQoL,randomized controlled trial,False,Outcome does not match PICOS criteria
305,305,patients with liver tumors,novel ablation confirmation method,visual inspection and anatomical landmarks-based measurements,"MAM, LTP-free survival",randomized controlled trial,False,Population and intervention do not match PICOS criteria
306,306,sorafenib pretreated advanced HCC with MET overexpression,tepotinib,not specified,progression-free survival,Phase 1b/2 study,False,Comparison not specified; study design is not RCT
307,307,HCC patients eligible for TACE,dexamethasone,placebo,PES incidence,randomized controlled trial,False,Population and intervention do not match PICOS criteria
308,308,families with DIAD,not specified,not specified,development of CMHs,longitudinal evaluation,False,"Population, intervention, and study design do not match"
309,309,advanced/metastatic GIST patients,ilixadencel,not specified,"tumor response, PFS",single arm phase I trial,False,"Population, comparison, and study design do not match"
302,302,not applicable,not applicable,not applicable,not applicable,not applicable,False,Abstract too short or empty
310,310,patients with HBV-related HCC,not specified,not specified,HCC recurrence,not specified,False,Does not mention immune checkpoint inhibitors or randomized controlled trial design.
311,311,patients with HER2-positive breast cancer,trastuzumab,not specified,pathological complete response,not specified,False,Population and intervention do not match the target criteria.
312,312,patients with hepatocellular carcinoma,clinical decision support system,handbook only,nursing practices and patient outcomes,randomized controlled trial,False,Intervention and outcome do not match the target criteria.
313,313,patients with HCC,not specified,not specified,microvascular invasion and prognosis,not specified,False,Does not mention immune checkpoint inhibitors or randomized controlled trial design.
314,314,"patients with cancer, including HCC",(89)Zr-IAB22M2C imaging,not specified,safety and utility of imaging,prospective study,False,Intervention and outcome do not match the target criteria.
315,315,patients with liver malignancies,3D printed models,not specified,decision-making in laparoscopic liver resections,prospective study,False,Intervention and outcome do not match the target criteria.
316,316,patients with liver cancers,transcutaneous electrical acustimulation,sham-TEA,GI symptoms,randomized controlled trial,False,Intervention and outcome do not match the target criteria.
317,317,patients with unresectable HCC,Tirapazamine with TAE,not specified,safety and tumor response,Phase 1 trial,False,Intervention and study design do not match the target criteria.
318,318,"patients with advanced cancer, including HCC",nivolumab,not specified,hyperprogressive disease,retrospective study,False,Study design does not match the target criteria.
319,319,"patients with advanced malignancies, including HCC",spartalizumab,not specified,safety and preliminary antitumor activity,Phase 1 study,False,Study design does not match the target criteria.
